Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 28 of 28 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/12
End: 08/31/14
Due: 08/31/15
Phase: N/A
Priority: Normal
Start: 08/15/20
End: 10/15/20
Due: 10/15/21
Phase: N/A
Priority: Normal
Start: 09/30/10
End: 12/31/14
Due: 12/31/15
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation | NCT01660633 | Acrotech Biopharma Inc. | user2@example.com | None | 2012-12-31 | 2014-08-31 | 2015-08-31 | - | - | 2025-07-14 |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Acrotech Biopharma Inc. | user2@example.com | None | 2020-08-15 | 2020-10-15 | 2021-10-15 | - | - | 2025-07-14 |
| To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | NCT01222780 | Acrotech Biopharma Inc. | user2@example.com | None | 2010-09-30 | 2014-12-31 | 2015-12-31 | - | - | 2025-07-14 |